The study of Cheetah Medical's NICOM Noninvasive Cardiac Output & Hemodynamic Monitoring System demonstrated promising results in patients with pulmonary hypertension (PH).
The US Food and Drug Administration cleared and CE marked NICOM monitoring system uses the company’s proprietary BIOREACTANCE Technology to deliver noninvasive cardiac output (CO) and other vital hemodynamic monitoring parameters, useful for fluid management and drug titration.
In the study, the Cheetah Medical NICOM monitoring system was compared with two gold-standard methods which are invasive, the pulmonary artery catheter, also known as Swan-Ganz catheter, and the Fick method.
The NICOM system provided equally accurate and precise measurements to the standard methods, but was completely non-invasive.
The University of Chicago Medicine professor and principle investigator of the study Stuart Rich said with the validation of a simple noninvasive technique to measure cardiac output in these patients, physicians should now be able to evaluate their patients’ status frequently, and better judge the efficacy of their treatments.